About Neovasc (NASDAQ:NVCN)
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVCN
CUSIPN/A
Phone604-270-4344
Debt
Debt-to-Equity Ratio-0.89%
Current Ratio0.77%
Quick Ratio0.75%
Price-To-Earnings
Trailing P/E Ratio-0.13
Forward P/E Ratio-0.54
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.39 million
Price / Sales9.21
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-0.11
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-22,900,000.00
Net Margins-439.15%
Return on Equity-85.81%
Return on Assets-25.28%
Miscellaneous
Employees147
Outstanding Shares1,012,850,000
Neovasc (NASDAQ:NVCN) Frequently Asked Questions
What is Neovasc's stock symbol?
Neovasc trades on the NASDAQ under the ticker symbol "NVCN."
How were Neovasc's earnings last quarter?
Neovasc Inc. (NASDAQ:NVCN) issued its quarterly earnings data on Tuesday, March, 29th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.04. The medical equipment provider earned $2.24 million during the quarter, compared to analyst estimates of $3.26 million. Neovasc had a negative return on equity of 85.81% and a negative net margin of 439.15%. View Neovasc's Earnings History.
When is Neovasc's next earnings date?
What price target have analysts set for NVCN?
2 brokers have issued 12 month target prices for Neovasc's shares. Their predictions range from $0.50 to $2.00. On average, they anticipate Neovasc's share price to reach $1.25 in the next twelve months. View Analyst Ratings for Neovasc.
Are investors shorting Neovasc?
Neovasc saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 10,229,047 shares, an increase of 121.3% from the March 15th total of 4,622,910 shares. Based on an average daily trading volume, of 85,156,416 shares, the days-to-cover ratio is currently 0.1 days. Approximately 11.4% of the shares of the company are sold short.
Who are some of Neovasc's key competitors?
Some companies that are related to Neovasc include Alphatec (ATEC), Invuity (IVTY), Obalon Therapeutics (OBLN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), Interpace Diagnostics Gr (IDXG), AIT Therapeutics (AITB), Valeritas (VLRX), Cytori Therapeutics (CYTX), InVivo Therapeutics (NVIV), Alliqua BioMedical (ALQA), Neurometrix (NURO), Amedica (AMDA), STRATA Skin Sciences (SSKN), Avinger (AVGR), TearLab (TEAR) and Lombard Medical Technologies (EVARF).
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Paul L. Geyer, Independent Chairman of the Board
- Fred Colen, President, Chief Executive Officer
- Christopher Clark, Chief Financial Officer, Corporate Secretary
- Brian McPherson, Chief Operating Officer
- Vicki Lee Bebeau, Vice President - Clinical Affairs
- Randy Lane, Vice President - Research & Development
- Alexei J. Marko, Director
- Jane H. Hsiao Ph.D., Independent Director (Age 69)
- Douglas Glen Janzen, Independent Director
- William O'Neill, Independent Director (Age 61)
Has Neovasc been receiving favorable news coverage?
News stories about NVCN stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neovasc earned a coverage optimism score of 0.07 on Accern's scale. They also gave news headlines about the medical equipment provider an impact score of 45.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Neovasc?
Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neovasc's stock price today?
One share of NVCN stock can currently be purchased for approximately $0.0490.
How big of a company is Neovasc?
Neovasc has a market capitalization of $49.63 million and generates $5.39 million in revenue each year. The medical equipment provider earns $-22,900,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Neovasc employs 147 workers across the globe.
How can I contact Neovasc?
Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, Richmond A1, V6V 2J7. The medical equipment provider can be reached via phone at 604-270-4344 or via email at [email protected]
MarketBeat Community Rating for Neovasc (NVCN)
MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe NVCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neovasc (NASDAQ:NVCN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Neovasc in the last 12 months. Their average twelve-month price target is $1.25, suggesting that the stock has a possible upside of 2,451.02%. The high price target for NVCN is $2.00 and the low price target for NVCN is $0.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.25 | $3.35 | $3.35 | $6.3333 |
| Price Target Upside: | 2,451.02% upside | 544.23% upside | 544.23% upside | 313.94% upside |
Neovasc (NASDAQ:NVCN) Consensus Price Target History
Neovasc (NASDAQ:NVCN) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Neovasc (NASDAQ:NVCN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Neovasc (NASDAQ NVCN) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 6.86%
Neovasc (NASDAQ NVCN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Neovasc (NASDAQ NVCN) News Headlines
| Source: |
|
Neovasc (NASDAQ:NVCN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neovasc (NASDAQ:NVCN) Income Statement, Balance Sheet and Cash Flow Statement
Neovasc (NASDAQ NVCN) Stock Chart for Sunday, April, 22, 2018
Loading chart…
